# Phenylacetamide compounds and an analgesic composition containing them.

## Abstract
A phenylacetamide compound of the general formula

## Claims
CLAIMS 1. A phenylacetamide compound of the general formula EMI41.1 wherein R1 is an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group having 2 to 4 carbon atoms, R2 is an alkenyl group having 3 to 6 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms or tetrahydrofurfuryl group,X is an alkoxy group having 1 to 3 carbon atoms, n is an integer of 0 to 2, Y isEMI41.2 which R3 is a hydrogen atom, arhydroxyl group or an aikoxyl group having 1 to 3 carbon atoms, m is zero or 1, i is an integer of 3 to 5 or a pharmaceutically acceptable salt thereof 2. A compound as claimed in Claim 1, wherein n is zero. 3. A compound as claimed in Claim 1, wherein n is 1. 4. A compound as claimed in Claim I, wherein n is 2. 5. A compound as claimed in Claim 3, wherein X is a methoxy group and is in the 4 position of the benzene ring. 6. A compound as claimed in Claim 5, wherein R1 is a methyl group, R2 is an allyl group and Y is a 2 phenylethyl group. 7. A compound as claimed in Claim 5, wherein R1 is a methyl group, Rz is a cyclopropylmethyl group and Y is a 2 phenylethyl group. 8. A compound as claimed in Claim 5, wherein R1 is a methyl group, R2 is a tetrahydrofurfuryl group and Y is a 2 phenylethyl group. 9. An analgesic composition comprising a therapeutically effective amount of at least one compound as claimed inClaim 1 and one or more pharmaceutically acceptable carriers or diluents. 10. For use in alleviating pain, a therapeutically effective amount of at least one compound as claimed inClaim 1. A U S T R IAN C L A I M S 1. A process for producing a phenylacetamide compound of the general formula EMI43.1 wherein R1 is an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group having 2 to 4 carbon atoms, R2 is an alkenyl group having 3 to 6 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms or tetrahydrofurfuryl group,X is an alkoxyL group having 1 to 3 carbon atoms, n is an integer of 0 to 2, Y isEMI43.2 in which R3 is a hydrogen atom, a hydroxyl group or an alkoxyl group having 7 to 3 carbon atoms, m is zero or is an integer of 3 to 5 or a pharmaceutically acceptable salt thereof, comprising the step of reacting a phenylacetic acid of the general formula II EMI43.3 wherein X and n have the meaning given above, or a reactive functional derivative thereof with a compound of general formula III EMI44.1 wherein Y, R1 and R2 have the meaning given above. 2. A process as claimed in Claim 1 wherein Y in the compound of formula III isEMI44.2 and R3 is a hydroxyl group protected by a protective group and the method includes the further step of removing the protective group from the reaction product of the compounds of formulae II and III . 3. A process for producing a phenylacetamide compound of the general formula EMI44.3 wherein R1 is an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group having 2 to 4 carbon atoms,R2 is an alkenyl group having 3 to 6 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms or tetrahydrofurfuryl group,X is an alkoxylgroup having 1 to 3 carbon atoms, n is an integer of 0 to 2, Y isEMI44.4 in which R3 is a hydrogen atom, a hydroxyl group or an alkoxyl group having 1 to 3 carbon atoms, m in zero or 1, l is an integer of 3 to 5 or a pharmaceutically acceptable salt thereof, using known starting materials and one or more process steps known per se. 4. A process as claimed in any preceding Claim, wherein n is zero. 5. A process as claimed in any one of Claims 1 to 3, wherein n is 1. 6. A process as claimed in any one of Claims 1 to 3, wherein fl is 2. 7. A process as claimed in Claim 5, wherein X is a methoxy group and is in the 4 position of the benzene ring. 8. A process as claimed in Claim 7, wherein R1 is a methyl group, R2 is an allyl group and Y is a 2 phenylethyl group. 9. A process as claimed in Claim 7, wherein R1 is a methyl group, R2 is a cyclopropylmethyl group and Y is a 2 phenylethyl group. 10. A process as claimed in Claim 7, wherein R1 is a methyl group, R2 is a tetrahydrofurfuryl group and Y is a 2 phenylethyl group. 11. A method of alleviating pain using a therapeutically effective amount of a phenylacetamide compound of the general formula EMI45.1 wherein R1 is an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group having 2 to 4 carbon atoms, R2 is an alkenyl group having 3 to 6 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms or tetrahydrofurfuryl group, X is an alkoxy group having 1 to 3 carbon atoms, n is an integer of 0 to 2, Y isEMI46.1 in which R is a hydrogen atom, a hydroxyl group or an alkoxyl group having 1 to 3 carbon atoms, m is zero or 1, is an integer of 3 to 5 or a pharmaceuticalty acceptable salt thereof.

## Description
This invention relates to phenylacetamide compounds exhibiting strong analgesic activity. Many compounds which have an acetamide skeleton have been reported to have an analgesic activity in the literature, such as Acta Harm. Sinica, Vol. 11, pages 108 to 113 1964 , J. Pharm. Sci., Vol. 55, pages 1093 to 1096, 1966 , and Austrian Patent No. 221,508.These compounds are amide compounds of phenylacetic acids with anilines, namely, anilides and in these compounds, it has been reported in J. Pharm. Sci, Vol. 55, pages 865 to 887, 1966 , J. Med. Chem. Vol. 17, pages 721 to 752, 1964 that compounds wherein the nitrogen atom of the amide group is connected through a hydrocarbon chain to the benzine ring exhibit decreased analgesic activity compared with the compounds wherein the nitrogen atom of amide group is directly attached to the benzene ring such as anilides. The present invention resides in one aspect in a phenylacetamide compound of the general formula EMI1.1 wherein R1 is an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group having 2 to 4 carbon atoms, R2 is an alkenyl group having 3 to 6 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms or tetrahydrofinfuryl group,X is an alkoxyl group having 1 to 3 carbon atoms, n is integer of 0 to 2, Y isEMI1.2 EMI1.3 in which R3 ia a hydrogen atom, a hydroxyl group or alkoxyl group having 1 to 3 carbon atoms, m is zero or 1 i is an integer of 3 to 5 or a pharmaceutically acceptable salt thereof. In a further aspect, the invention resides in an analgesic composition comprising a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable diluents or carriers. In yet a further aspect, the invention in a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof for use in alleviating pain. It has been found that the phenylacetamide compounds of the general formula I EMI2.1 wherein R1 is an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group having 2 to 4 carbon atoms, R2 is an alkenyl group having 3 to 6 carbon atoms, a cycloalkyl group having 4 to 7 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms or tetrahydrofurfuryl group, X is an alkoxy group having 1 to 3 carbon atoms, n is an integer of 0 to 2, Y isEMI2.2 in which R3 is a bydrogen atom, a hydroxyl group or an alkoxy group having 1 to 3 carbon atoms, m is zero or 1, e is an integer of 3 to 5, and the pharmaceutically acceptable salts thereof show an inhibitory effect on writhing test induced by acetic acid.As expected from this property, the compounds of formula I and their pharmaceutically. acceptable salts thereof possess an analgesic action and are useful as therapeutically active agents for various types of pain. In the compounds of this invention, the nuclear substituent X in the phenylacetyl group may be in any position and as that substituent, methoxy, methoxy and propoxy groups may be employed. Preferably, the X substituent is a methoxy group, and n is preferably one.As the substituent Y , 2 phenylethyl, 2 p methoxyphenyl ethyl, 2 p ethoxyphenyl ethyl, 2 p propoxyphenyl ethyl groups and 1 or 2 indanylmethyl, 1 or 2 indanyl groups and 1, 2, 3, 4 terahydro 1 or 2 naphthyl, 2, 2, 3,4 tetrahydro 1 or 2 napththylmethyl groups are preferred, with the 2 phenylethyl group being the most preferred.As the substituent R1 , methyl, ethyl and propyl groups and 2 hydroxyethyl, 3 hydroxypropyl and 4 hydroxybutyl groups may be employed, the preferred examples being ethyl and methyl groups and the most preferred example being a methyl group. An alkenyl group having 3 to 6 carbon atoms, a cycloalkyl group having 4 to 7, a cycloalkylalkyl group having 4 to 7 carbon atoms or a tetrahydrofurfuryl group is employed in this invention as the substituent R2 . Preferred examples are alkenyl group, cycloalkylalkyl group and tetrahydrofurfuryl group, and most preferred examples are allyl, tetrahydrofurfuryl and cyclopropylmethyl groups. Compounds carrying as substituents R1 and R2 of the amino group, di alkyl groups such as dimethyl, diethyl and dipropyl groups become weak in pharmacological activity. Of the compounds of this invention, N 2 phenylethyl N 2 N methyl N tetrahydrofurfurylamino ethyl 4 methOxy phenylacetamide, N 2 phenylethyl N 2 N methyl N allyl amino ethyl 4 methoxyphenylacetamide and N 2 phenylethyl N f 2 N methyl N cyclopropylmethylamino ethyl 4 methoxy phenylacetamide are most preferred Compounds of the general formula I can be prepared, for example, by a process wherein a phenylacetic acid or a reactive functional derivative of a phenylacetic acid of the general formula it EMI4.1 wherein X and n have the same meaning as given above, is reacted with a compound of the general formula III EMI5.1 wherein Y, R1 and R2 have the same meanings as given above, and if desired, hydrolyzing the obtained compound to obtain the end compounds. When the compound of the general formula III above is a compound carrying a hydroxyl group on the benzene nucleus, such compound is preferably protected in the hydroxyl group with benzyl or the like prior to the reaction with a phenylacetic acid of the general formula 11 . These protective groups can easily be cleaved in usual manner. The phenylacetic acid compounds of the general formula II above, used as starting materials, can easily be prpared according to methods described in the literature. Examples of such compounds include phenylacetic acid, 2 , 3 or 4 methoxyphenylacetic acid, 2 , 3 or 4 ethoxyphenylacetic acid, 2 , 3 or 4 propoxyphe.nylacetic acid, 2,3 , 2,4 , 2,5 , 2,6 , 3,4 or 3,5 dimethoxszphenylacetic acid, 2,3 , 2,4 , 2,5 , 2,6 , 3,4 or 3,5 diethoxyphenylacetic acid, 2,3 , 2,4 , ,5 , 2,6 , 3,4 or 3,5 dipropoxyphenylacetic acid, 3 methoxy 4 ethoxyphenylacetic acid, 3 methoxy4 propoxyphenylacetic acid, 4 methoxy 3 propoxyphenyl acetic acid, 4 methoxy 3 ethoxyphenylacetic acid.In the above process, reactive functional derivatives of such phenylacetic acids are also used as starting materials. Examples of such derivatives include car boxylic acid derivatives, such as acid halides, esters, acid anhydrides, mixed acid anhydrides and a reaction product of such carboxylic acid with a carbodiimide. These reactive functional derivatives can easily be derived from the phenylacetic acids of the general formula II according to usual techniques known in this art. For example, the acid chloride can easily be obtained by refluxing for several hours the phenyl acetic acid with thionyl chloride in the absence of any solvent or in dry benzene. The compounds of the general formula III above, used as starting materials, can easily be prepared by reacting a compound of the general formula IV Y NH2 IV wherein Y has the same meanings as given above, with chloroacetyl chloride in aqueous dioxane in the presence of sodium bicarbonate, and reacting the obtained compound of the general formula V Y R C0CH2Cl V wherein Y has the same meaning as given above, with a compound of the general formula VI EMI7.1 wherein R1 and R2 have the same meaning as given above, and then hydrogenating the resulting compound of general formula VII. EMI7.2 wherein Y, R1 and R2 have the same meaning as given above, using aluminum lithium hydride.Alternatively, a compound of the general formula V above can be reacted with a compound of the general formula VIII R1NH2 VIII wherein R1 has the same meaning as given above, or a compound of the general formula IX R2NH2 ix wherein R2 has the same meaning as given above, and the obtained compound can be treated with a compound of the general formula X R2Z x wherein Z is a halogen atom, R2 has the same meaning as given above, or a compound of the general formula XI R1Z XI wherein Z and R1 has the same meaning as given above, and then the obtained compound can be hydrogenated using aluminum lithium hydride to obtain the compound of the general formula III above. Examples of the compounds of the general formula III above include N 2 phenylethyl N methyl N allyl ethylenediamine, N 2 phenylethyl N ethyl N allylethylenediamine, N 2 phenylethyl N propyl N allylethylenediamine, N 2 phenylethyl N methyl N 3,3 dimethylallyl ethylenediamine, N 2 phenylethyl N ethyl N 3,3dimethylallyl ethylenediamine, N 2 phenylethyl N propyl N 3,3 dimethylallyl ethylenediamine, N 2 4 methoxyphenyl ethyl N methyl N 3,3 dimethylallyl ethylenediamine, N 2 4 methoxyphenylsethyl N ethyl N 3,3 dimethylallyl ethylenediamine, N 2 4 methoxyphenyl ethyl Ni propyl N 3,3 dimethyl allyl ethylenediamine, N 2 phenylethyl N 2 hydroxyethyl N allyethylenediamine, N 2 phenylethyl N1 methyl N tetrahydrofurfurylethylenediamine, N 2 phenylethyl N ethyl N tetrahydrofurfurylethylenediamine, N 2 phenylethyl N propyl N tetrahydrofurfurylethylenediamine, N 2 4 methoxyphenyl ethyl N methyl N tetrahydro furfurylethylenediamine, N 2 4 methoxyphenyl ethylN ethyl N tetrahydrofurfurylethylenediamine, N 2 4 methoxyphenyl ethyl N propyl N tetrahydrofurfuryl ethylenediamine, N 2 4 athoxyphenyl ethyl N methylN tetrahydrofurfurylethylenediamine, N 2 4 ethoxy phenyl ethyl N ethyl N tetrahydrofurfurylethylene diamine, N 2 4 athoxyphenyl ethyl N propyl N tetrahydrofurfurylethylenediamine, N 2 4 propoxyphenyl ethyl N methyl N tetrahydrofurfurylethylenediamine, N 2 4 propoxyphenyl ethyl N ethyl N tetrahydrofurfuryl ethylenediamine, N 2 4 propoxyphenyl ethyl N propylN tetrahydrofurfurylethylenediamine, N 2 phenylethylN methyl N cyclopropylmethylethylenediamine, N 2phenylethyl N ethyl N cyclopropylmethylethylenediamine, N 2 phenylethyl N propyl N cyclopropylmethylethylenediamine, N 2 phenylethyl N methyl N cyclo hexylethylenediamine, N 2 phenylethyl N ethyl N cyclohexylethylenediamine, N 2 phenylethyl N propyl N cyclohexylethylenediamine, N 2 4 methoxyphenyl ethyl N methyl N cyclopropylmethylethylenediamine, N 2 4 methoxyphenyl ethyl N methyl N cyclohexylethylenediamine, N 2 4 methoxyphenyl ethylN ethyl N cyclopropylmethylethylenediamine, N 2 4 methoxyphenyl ethyl N ethyl N cyclohexylethylene diamine, N 2 4 methoxyphenyl ethyl N propyl N cyclopropylmethylethylenediamine, N 2 4 methoxyphenyl ethyl N propyl N cyclohexylethylenediamine, N 2 4 ethoxyphenyl ethyl N methyl N cyclopropylmethyl ethylenediamine, N 2 4 ethoxyphenyl ethyl N ethyl N cyclohexylethylenediamine, N 2 4 ethoxyphenyl ethylN ethyl N cyclopropylmethylethylenediamine, N 2 4 propoxyphenyl ethyl N 1 propyl N cyclopropylmethyl ethylenediamine, N 2 4 benzyloxyphenyl ethyl N methyl N cyclopropylmethylethylenediamine, N 2 4 benzyloxy phenyl ethyl N methyl N cyclohexylethylenediamine,N 2 4 benzyloxyphenyl ethyl N ethyl NI cyclopropyl methylethylenediamine, N 2 4 benzyloxyphenyl ethylN ethyl N cyclohexylethylenediamine, N 2 4 benzyloxyphenyl ethyl N propyl N cyclohexylethylenediamine, N 2 phenylethyl N methyl N cyclobutyl ethylenediamine, N 2 phenylethyl N ethyl N cyclobutylethylenediamine, N 2 phenylethyl N propyl N cyclo butylethylenediamine, N 2 4 methoxyphenyl ethyl N mathyl N cyclobutylethylenediamine, N 2 4 methoxyphenyl ethyl N ethyl N cyclobutylethylenediamine, N 1,2,3,4 tetrahydro 1 naphthylmethyl N methyl N allylethylenediamine, N 1,2,3,4 tetrahydro 1 naphthylmethyl N methyl Nt 3,3 dimethylallyiethylene diamine, N 1,2,3,4 tetrahydro 1 naphtyhlmethyl N methyl N tetrahydrofurfurylethylenediamine, N 1,2,3,4tetrahydro 2 naphthyl N methyl N allylethylenediamine,N 1,2,3,4 tetrahydro 2 naphthyl N methyl N 3,3 dimethylallyl ethylenediamine, N 1,2,3,4 tetrahydro 2naphthyl N methyl N tetrahydrofurfurylethylenediamine, N 1,2,3,4 tetrahydo 1 naphthylmethyl N methyl N cyclopropylmethylethylenediamine, N 1,2,3,4 tetrahydro2 naphthyl N methyl N cyclopropylmethylethylenediamine,N 2 indanyl N methyl N allylethylenediamine, N 2indanyl N methyl N 3,3 dimethylallyl ethylenediamine, N 2 indanyl N meçhyl N tetrahydrofurfurylethylene diamine, N 2 indanyl N methyl N cyclopropylmethylethylenediamine, N 1 indanylmethyl N methyl N allyl ethylenediamine, N 1 indanylmethyl N methyl N 3,3dimethylallyl ethylenediamine, N 1 indanylmethyl N methyl N tetrahydrofurfurylethylenediamine, N 1 indanylmethyl Nt methyl N cyclopropylmethylethylene diamine, etc. The amidation described above in the reaction of the compound of the general formula 11 with the compound of the general formula III can be carried out according to methods known per se. For example, when the phenylacetic acid compound of the general formula II is used as a starting material, a mixture of the phenylacetic acid compound and the compound of the general formula III above in a proportion of about 1 to 0.8 mols per mol of the phenylacetic acid compound is heated to about 50 to about 2000C, preferably 120 to 1800C, for about 10 to about 24 hours, preferably 15 to 20 hours in an or inert organic solvent such as xylene tolueneAlternatively, a mixture of the phenylacetic acid compound and the compound of the general formula III in proportion of about 1 to about 0.8 mols per mol of the phenylacetic acid compound in an inert organic solvent such as ethers, e.g., dioxane, tetrahydrofuran, etc., aromatic hydrocarbons, benzene, xylene, toluene, halogenated hydrocarbons, e.g., dichloromethane, dichloroethane, chloroform, etc., and an adequate amount of a condensing agent is added to the mixture with ice cooling and stirring, and then the mixture is stirred at room temperature or at about 50 to about 150 C, preferably 50 to 1200C for about 1 to about 10 hours, preferably 2 to 5 hours, or the compound of the general formula III is added tf a mixture of the phenylacetic acid compound in a proportion of about 1 to about 1.2 mols per mol of the compound of the general formula III and an adequate amount of a condensing agent in an inert organic solvent such as those described above with cooling and stirring, and then the mixture is stirred at room temperature or at about 50 to about 150 C, preferably 50 to 1200C, for about 1 to 10 hours, preferably 2 to 5 hours. A suitable amount of the condensing agent which can be used in this process is from about 1 to about 1.3 mols, preferably 1 mol, per mol of the compound of the general formula II . Suitable examples of the condensing agent which can be used in this process include phosphorus oxychloride, phosphorus pentoxide, phosphorus trichloride, phosphorus tribromide, phosphorus pentabromide, polyphosphoric acid,polyphosphoric acid esters, methyl dichlorophosphite, dimethyl chlorophosphite, diethyl chlorophosphite, ethylene chlorophosphite, phenylene chlorophosphate, ethyl di chlorophosphate, phenyl dichlorophosphine oxide, dibenzyl chlorophosphine oxide, and tetraethyl pyrophosphite. When a reactive functional derivative of the phenylacetic acid compound is used as a starting material, for example, the acid chloride is reacted with the compound of the general formula III above in a proportion of about 1 to about 0.8 mols per mol of the phenylacetic acid halide of the general formula II above at about 0 to about 100 C, preferably room temperature to 70 C, for about 1 to 5 hours, preferably 2 to 3 hours, in an inert solvent, such as diethyl ether and water as well as those described above.This procedure is preferably carried out by dissolving a compound of the general formula III in an inert solvent together with an adequate amount of a basic substance with cooling and stirring, adding a solution of a slightly excess amount of or an equimolar amount of an acid halide of the phenylacetic acid compound in an inert solvent and refluxing the mixture for several hours. In this case, suitable examples of the basic substance include a tertiary organic base such as triethylamine or pyridine, or an inorganic base such as caustic alkal sodium carbonate or potassium carbonate. This reaction can also be carried out using 4 N,N dimethylamine pyridine as catalyst. The reaction product is washed with an alkaline solution, for example, an aqueous solution of about 5 to about 10 by weight of an alkali metal hydroxide, such as NaOH, KOH, LiOH, etc., an alkaline earth metal hydroxide such as Ca OH 2, Mg OH 2, etc., then extracted with an inert solvent such as ether, The resu ant then solvent layer is dried, and concentrated under reduced pressure. The residue is distilled under reduced pressure to obtain the end product. Alternatively, the washed reaction mixture is concentrated under reduced pressure and the residue is purified by column chromatography using active alumina to obtain the end product. The compound of this invention in the free form is a viscous oily substance and is soluble in usual organic solvents, such as chloroform, alcohols, e.g., methanol, ethanol, etc., esters, e.g., ethyl acetate, methyl acetate, etc., ethers, e.g., dimethyl ether, diethyl ether, tetrahydrofuran, dioxane, etc. The resulting compound of the general formula I a having free amino group can be converted according to usual methods to pharmaceutically acceptable acid addition salts thereof. For example, the compound of the general formula I is dissolved in diethylether, and hydrogen chloride in an equimolar or excess amount is bubbled into the ether solution, then the precipitated crystals are collected by filtration and, if desired, are recrystallized from a suitable solvent whereby the compound can be converted into its hydrochloric acid salt. Suitable examples of such pharmaceutically acceptable salts include, in addition to hydrochloric acid salts, sulfonic acid salts frydrobromic acid salts, citric acid salts, succinic acid salts, and lactic acid salts.These salts are crystalline substances or gelatin like semi solid substances having glassy appearance, soluble in water and alcohols. These pharmaceutically acceptable acid addition salts of the compounds of this invention have as high a pharmacological effect as the corresponding compounds containing free amino group. The phenylacetamide compounds of this invention possess strong analgesic activity, and are useful as anodynes. The compound of the general formula I and the pharmaceutically acceptable salts thereof of the present invention can be administered to mammals including humar3by oral, intravenous, intramuscular or intrarectal administration, and can be formulated into pharmaceutical compositions together with ordinary pharmaceutically acceptable carriers. Various dosage forms of the therapeutic agents as an analgesic agent can be selected according to the purpose of the therapy. Typical dosage forms which can be used are tablets, pills, powders, liquid preparations, suspensions, emulsions, granules, capsules, suppositories, and injectable preparations. In molding the pharmaceutical composition into a tablet form, a wide variety of conventional carriers known in the art can be used. Examples of suitable carriers are excipients, such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaolin and talc, binders, such as gum arabic powder, tragacanth powder, gelatin, and ethanol, and disintegrants, such as laminaria and agar. The tablets, if desired, can be coated, and made into sugar coated tablets, gelatin coated tablets, enteric coated tablets, filmcoated tablets, or tablets coated with two or more layers. When the pharmaceutical composition is formulated into an injectable preparation, the resulting solution and suspension are preferably sterilized, dnd are isotonic with respect to the blood. In formulating the pharmaceutical composition into the form of a solution or suspension, all diluents customarily used in the art can be used. Examples of suitable diluents are water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, and 4sorbitan esters. Sodium chloride, glucose or glycerol may be incorporated into an analgesic agent in an amount sufficient to prepare isotonic solutions.The therapeutic agent may further contain ordinary dissolving acids, buffers, pain alleviating agents, and preservatives, and optionally coloring agents, perfumes, flavors, sweeteners, and other drugs. The dosage of the compound of this invention is suitably selected according to the purpose of use, the symptoms, etc. Usually, a preferred dosage of the compound of this invention is about 0.5 to 10 mg kg of body weight per day in multiple doses. This invention is further illustrated in more detail by way of examples wherein the melting points or the boiling points of the products obtained are uncorrected. Unless otherwise indicated, all parts, percents, ratios and the like are by weight. REFERENCE E.YA2LE 1 To an aqueous solution of 59.5 g of 2 4 methoxy phenyl ethylamine hydrochloride and 120 g of sodium bicarbonate in 800 ml of dioxane and 1000 ml of water was added dropwise .60 g of chloroacetyl chloride with ice cooling and stirring and then the mixture was stirred for 2 hours at room temperature. The reaction mixture was concentrated under reduced pressure and an adequate amount of water was added to the residue, and then the precipitate was collected and recrystallized from chloroform n hexane to obtain 50.5 g of N 2 4 iiethoxyphenyl ethyl chloroacetamide. Admixture of 8 g of N 2 4 methoxyphenyl ethyl chioroacetamide and 50 g of a 40 methanol solution of methylamine was heated for 4 hours at 1000C in a sealed tube. After cooling, the reaction mixture was concentrated under reduced pressure and an adequate amount of a 10 aqueous. solution of sodium hydroxide was added to the residue to make the liquid alkali, and then tlie alkaline mixture was extracted with benzene.The benzene layer was washed with water, dried and concentrated under reduced pressure to obtain 7.5 g of N 2 4 methoxyphenyl ethylAmethylaminoacetamide. A mixture of 7.5 g of N 2 4 methoxyphenyl ethyl methylaminoacetamide, 4 g of 3,3 dimethylallyl chloride, 13 g of potassium carbonate and 0.5 g of sodium iodine in 140 ml of ethanol and 50 ml of water was heated under reflux for 5 hours. The reaction mixture was concentrated under reduced pressure and an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the residue to make the liquid alkali, and then the alkaline mixture was extracted with benzene.The benzene layer was washed with water, dried and concentrated under reduced pressure to obtain 6.8 g ofN 2 4 methoxyphenyl ethyl N methyl N 3,3 dimethyl ailyl amino acetamide To a suspension of 5.3 g of aluminum lithium hydride in 50 ml of ether was added dropwise 6.8 g of N 2 4 hOxyphenyl ethyl N methyl N 3,3 dimethylallyl amino acetamide with ice cooling and stirring, and the mixture was stirred for 1 hour at room temperature and then heated under reflux overnight. After cooling, an adequate amount of a 10 aqueous solution of sodium hydroxide was added dropwise to the reaction mixture with ice cooling and stirring until the evolution of hydrogen gas ceased. The mixture was filtered and an organic phase was separated, dried and concentrated under reduced pressure.The residue was distilled under reduced pressure 130 135 C 0.5 mmHg to obtain 4.9 g of N 2 4 methoxyphenyl ethyl N methyl N 3,3 dimethylallyl etVylenediamine. IR absorption spectrum neat vNH 3300 cm 1 Elementary analysis as C17H28NzO C H N Calcd. 73.86 10.21 10.14 Found 73.73 10.18 10.21 ZL R spectrum CDCl3 6 1.65 s, 3H , 1.75 s, 3H , 2.20 s, 3H , 2.3 3.1 m, llH , 3.80 s, 3H , 5.1 5.4 m, 1H , 6.80 d, 2H , 7.14 d, 2H ,REFERENCE EXAMPLE 2 To a solution of 38 g of 2 phenylethylamine hydrochloride and 80 g of sodium bicarbonate in 600 ml of dioxane and 700 ml of water was added dropwise 40 g of chloroacetyl chloride with ice cooling and stirring amd the mixture was stirred for 2. hours at room temperature.The reaction mixture was concentrated under reduced pressure and an adequate amount of water was added to the residue, and then the precipitate was collected and recrystallized from chloroform n hexane to obtain 36.2 g of N 2 phenylethyl chloroacetamide. A mixture of 36.2 g of N 2 phenylethyl chloroacetamide, 22.2 g of N methylcyclopropylmethylamine hydrochloride and 40.7 g of triethylamine in 200 ml of benzene was heated under reflux overnight. After cooling, an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the reaction mixture to make the liquid alkaline and an organic phase was separated, washed with water, dried and concentrated under reduced pressure to obtain 45.3 g of N 2 phenyl ethyl N methyl N cyclopropylmethyl amino acetamide. To a suspension of 14 g of aluminum lithium hydride in 1000 ml of ether was added dropwise a solution of 45.3 g of N 2 phenylethyl N methyl N cyclopropylmethyl rtmino3acetamide in 300 ml of ether with ice cooling and stirring, and the mixture was stirred for 1 hour at room temperature and then heated under reflux overnight. After cooling, an adequate amount of a 10 aqueous solution of sodium hydroxde was added to the reaction mixture with ice cooling and stirring until the evolution of hydrogen gas ceased The mixture was filtered and an organic phase separated, dried and concentrated under reduced pressure. The residue was distilled under reduced pressure 130 1350C 1 mmHg to obtain 31.9 g of N 2 phenylethyl N methyl N cyclopropylmethylethylene diamine.IR absorption spectrum neat vNH 3300 cml Elementary analysis as C15H24N2 Calcd. 77.53 10.41 12.06 Found 77.46 10.46 11.98NMR spectrum CDCL3 d 0 1.05 m, 5H , 1.8 s, 1H , 2.15 3.0 m, 13H , 7.2 s, 5H The following compounds can be prepared in a similar manner. The results obtained are shown in Table 1 below. Table 1. EMI24.1 EMI24.2 Com. SEP No. SEP Y SEP R1 SEP R2 SEP boiling SEP liquid SEP IR absorption tb SEP point SEP condition SEP spectrum tb 1 SEP SEP CH3 SEP CH2CH CH2 SEP 115 120 C SEP pale SEP yellow SEP NH 3300 SEP cm 1 tb SEP 1 SEP mmHg SEP oil tb 2 SEP SEP CH3 SEP CH2CH C CH3 2 SEP 120 123 C SEP colorless SEP NH 3300 SEP cm 1 tb SEP 1 SEP mmHg SEP oil tb 3 SEP SEP CH2CH2OH SEP CH2CH CH2 SEP 110 115 C SEP colorless SEP OH 3300 SEP cm 1 tb SEP 1 SEP mmHg SEP oil tb 4 SEP SEP CH3 SEP SEP 204 207 C SEP colorless SEP NH 3300 SEP cm 1 tb SEP 3 SEP mmHg SEP oil tb 5 SEP SEP CH3 SEP SEP 165 166 C SEP colorless SEP NH 3300 SEP cm 1 tb SEP 3 SEP mmHg SEP oil tb 6 SEP SEP CH2CH2CH3 SEP SEP 187 189 C SEP pale SEP yellow SEP NH 3300 SEP cm 1 tb SEP 4 SEP mmHg SEP oil tb EMI25.1 Com. SEP No. SEP Y SEP R1 SEP R2 SEP boiling SEP liquid SEP IR absorption tb SEP point SEP condition SEP spectrum tb SEP 7 SEP SEP CH3 SEP SEP 135 140 C SEP colorless SEP NH 3300 SEP cm 1 tb SEP 1 SEP mmHg SEP oil tb SEP 8 SEP SEP CH3 SEP SEP 163 165 C SEP colorless SEP NH 3300 SEP cm 1 tb SEP 5 SEP mmHg SEP oil tb SEP 9 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP NH 3300 SEP cm 1 tb SEP oil tb 10 SEP SEP CH3 SEP CH2CH C CH3 2 SEP 160 165 C SEP colorless SEP NH 3300 SEP cm 1 tb SEP 1 SEP mmHg SEP oil tb 11 SEP SEP CH3 SEP SEP 143 145 C SEP colorless SEP NH 3290 SEP cm 1 tb SEP 1 SEP mmHg SEP oil tb 12 SEP SEP CH3 SEP SEP 192 200 C SEP colorless SEP NH 3300 SEP cm 1 tb SEP 2 SEP mmHg SEP oil tb 13 SEP SEP CH3 SEP SEP 168 170 C SEP pale SEP yellow SEP NH 3300 SEP cm 1 tb SEP 2 SEP mmHg SEP oil tb The compounds were purified by column chromatography using active alumina and a mixture of benzene and ethyl acetate as eluent. EXAMPLE 1 To a solution of 3 g of N 2 phenylethyl N 2 hydroxyethyl N allylethylenediamine and 10 g of triethylamine in 50 ml of benzene was added dropwise a solution of 7 g of 4 methoxyphenylacetyl chloride in 50 ml of benzene with ice cooling and stirring, and the mixture was stirred for 1 hour at room temperature and then heated under reflux for 3 hours. After cooling, the reaction mixture was washed successively with a 10 aqueous solution of sodium hydroxide and water, dried and concentrated under reduced pressure.The residue was dissolved in 50 ml of ethanol containing 2 g of sodium hydroxide and the solution was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, and an adequate amount of water was added to the residue and the mixture was extracted with benzene. The benzene layer was washed with water, dried and concentrated under reduced pressure.The residue was purified by column chromatography using active alumina and a mixture of benzene and ethyl acetate as eluent to obtain 3 g of N 2 phenylethyl N 2 N 2 hydroxy ethyl N allylamino ethyl 4 me thoxyphenylacetamide. pale yellow oil IR absorption spectrum neat CO 1640 cm 1 OH 3400 cm 1 Elementary analysis as C24H32N2O3 C H N Calcd. 72.69 8.13 7.07 Found 72.73 8.25 6.92NMR spectrum CDC13 6 2.4 7.7 m, 17H , 3.72 s, 3H , 5.0 5.3 m, 2H , 5.5 6.0 m, 1H , 6.7 7.4 m, 9H EXAMPLE 2 To a solution of 3.4 g of 4 methoxyphenylacetic acid in 80 ml of benzene was added dropwise 3.2 g of phosphorus oxychloride with ice cooling and stirring and the mixture was stirred for 30 minutes at room temperature, and then 3 g of N 2 phenylethyl N methylN allylethylenediamine was added to the mixture and then the mixture was heated under reflux for 3 hours.After completion of the reaction, an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the reaction mixture to make the liquid alkalineThe alkaline.mixture was extracted with benzene, and the benzene layer was washed with water, dried and concentrated under reduced pressure. The residue was distilled under reduced pressure 170 180 C 0.5 mmHg to obtain 4.5 g of N 2 phenylethyl N 2 N methyl N allylamino ethyl3 4 methoxyphenylacetamide as a pale yellow substance. fl absorption spectrum neat CO2 1640 cm 1Elementary analysis as C23H30N2O2 C H N Calcd. 75.37 8.25 7.64 Found 75.27 8.45 7.39NMR spectrum DMSO d6 2.15 s, 3H , 2.2 3.7 m, 12H , 3.75 s, 3H , 4.9 5.4 m, 2H , 5.5 6.0 m, 1H , 6.7 7.3 m, 9H EXAMPLE 3 To a solution of 7.9 g of N 2 phenylethyl N methyl N tetrahydrofurfurylethylenediamine, 10 ml of triethylamine and 190 mg of 4 N,N dimethylamino pyridine in iDO ml of dichloromethane was added dropwise a solution of 6.5 g of 4 methoxyphenylacetyl chloride in 20 ml of dichloromethane with ice cooling and stirring and the mixture was stirred for 1 hour at room temperature.After completion of the reaction, an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the reaction mixture to make the liquid alkaline.An organic phase was separated, washed with water, dried and concentrated under reduced pressure. The residue was distilled under reduced pressure 2432450C 0.2 mmHg to obtain 9 g of N 2 phenylethyl N 2 N methyl N tetrahydrofurfurylamino ethyl 4 methoxyphenylacetamide. IR Absorption spectrum neat 1 vCO 1635 cmElementary analysis as C25H34N2O3 C H N Calcd. 73.14 8.35 6.82 Found 73.09 8.15 6.89NMR spectrum CDC13 6 1.2 4.15 m, 22H , 3.77 s, 3H , 6.7 7.4 m, 9H EXAMPLE 4 To a solution of 5 g of 3,4 dimethoxyphenylacetic acid in 20 ml of benzene was added dropwise 4 g of phosphorus oxychloride with ice cooling and stirring and the mixture was stirred for 30 minutes at room temperature. A solution of 4.6 g of N 2 phenylethyl N methyl N tetrahydrofurfurylethylenediamine in 20 ml of benzene was added to the mixture with ice cooling and stirring and the mixture was stirred for 30 minutes at room temperature and then heated under reflux for 3 hours.After completion of the reaction, an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the reaction mixture to make the liquid alkaline An organic phase was separated, washed with water dried and concentrated under reduced pressure. he residue was purified by column chromatography using active alumina and a mixture of benzene and ethyl acetate es eluent to obtain 5.3 g of N 2 phenylethyl N 2 lN methyl N tetrahydrofurfuryamino ethyll 3,4 dimethoxyphenylacetamide. pale yellow oil IR absorption spectrum neat vCO 1640 cm Elementary analysis as C26H36N2O4 C H N Calcd. 70.88 8.24 6.36 Found 70.97 8.22 6.21NMR spectrum CDC13 6 1.30 4.0 m, 22H , 3.85 s, 3H , 3.88 s, 3H , 6.6 7.4 m, 8H EXAMPLE 5 To a solution of 5 g of 4 methoxyphenylacetic acid in 30 ml of benzene was added dropwise 6 g of phosphorus oxychloride with ice cooling and stirring and the mixture was stirred for 30 minutes at room temperature.A solution of 6 g of N 1,2,3 4 tetrahydro l naphthylmethyl N methyl N tetrahydrofurfurylethylenediamine in 20 ml of benzene was added dropwise to the mixture. The mixture was stirred for 1 hour at room temperature and then heated under reflux for 3 hours. After cooling, an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the reaction mixture to make the liquid alkaline and the alkaline mixture was extracted with benzene, washed with water, dried and concentrated under reduced pressure.The residue was purified by columnchromatography using active alumina and a mixture of benzene and ethyl acetate as eluent to obtain 6.5 g of N 1,2,3,4 tetrahy2ro 1 naphthylmethyl N 12 N methyl N tetrahydrofurfurylamino ethyl 4 methoxyphenylacetamide. yellow oil IR absorpticn spectrum neat l vCO 1640 cm Elementary analysis as C28H38N203 H Calcd. 74.63 8.50 6.22 Found 74.50 8.45 5.95 NMR spectrum CDC13 6 1.0 4.1 m, 27H , 3.78 s, 3H , 6.6 7.3 m, 8H EXAMPLE 6 To a solution of 2 g of N 2 indanyl N methyl N cyciopropylmethylethylenediamine, 50 mg of 4 N,N dimethylamino pyridine and 3 g of triethylamine in 30 ml of dichloromethane was added dropwise a solution of 1.6 g of phenylacetyl chloride in 5 ml of dichloromethane with ice cooling and stirring. The mixture was stirred for 2 hours at room temperature.The reaction mixture was concentrated under reduced pressure and an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the residue to make the liquid alkaline. The alkaline mixture was extracted with benzene, and the benzene layer was washed with water, dried and concentrated under reduced pressure.The residue was purified by column chromatography using active alumina and a mixture of benzene and ethyl acetate as eluent to obtain 1.8 g of N 2 indanyl N t2 N methyl N cyclo propylmethyl aminoethyl phenylacetamide. pale yellow oil IR absorption spectrum neat vCO 1640 cm Elementary analysis as C24H30N2O C H N Calcd. 79.51 8.34 7.73 Found 79.39 8.29 7.81NMR spectrum CDC13 bt 0 1.0 m, 5H , 2.0 4.0 m, 14H , 3.80 s, 2H , 7.0 7.5 m, 9H EXAMPLE 7 To a solution of 10 g of N 2 4 benzyloxyphenyl ethyl N methyl N cyclopropylmethylethylenediamine and 8.3 g of 4 methoxyphenylacetic acid in 100 ml of benzene was added dropwise 7.7 g of phosphorus oxychloride with ice cooling and stirring. The mixture was stirred for 1 hour at room temperature and then seated under reflux for 5 hours.After completion of the reaction, an adequate amount of a 10 aqueous solution of sodium hydroxide was added to the reaction mixture to make the liquid alkaline and the alkaline mixture was extracted with benzene. The benzene layer was washed with water, dried and concentrated under reduced pressure, and the residue was purified by column chromatography using active alumina and a mixture of benzene and ethyl acetate as eluent to obtain 10 g of N 2 4 benzyloxyphenyl ethyl N 2 N methyl N cyclo propylmethyl aminoethyl 4 methoxyphenylacetamide. A solution of 10 g of N 2 4 benzyloxyphenyl ethyl N 12 N me thyl N cyclopropylmethyl aminoethyl 4 methoxy phenylacetamide, 3 ml of concentrated hydrochloric acid and 300 ml of ethanol was hydrogenated over 0.6 g of palladium chloride at room temperature under 4 atms. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. A solution of 9 g of diethylamine in 500 ml of diethylether was added to the residue and the precipitate was filtcred off, and the filtrate was concentrated under reduced pressure to obtain 4.8 g of N 2 4 hydroxy phenyl ethyl N t2 N methyl N cyclopropylmethyl aminoethyl 4 methoxyphenylacetamide as a pale yellow oil. IR absorption spectrum neat vOH 3250 cm vCO 1630 cm 1 Elementary analysis as C24H32N2O3 C H N Calcd. 72.69 8.13 7.07 Found 72.51 8.21 6.87NMR spectrum CDC13 6 0 1.1 m, 5H , 2.2 3.9 m, 15H , 3.76 s, 3H , 6.6 7.3 m, 8H , 8.38 br, 1H EXAMPLE 8 To a solution of 3.5 g of N 2 phenylethyl N methylN cyclopropylmethylethylenediamine, 5 ml of triethylamine and 20 mg of 4 N,N dimethylamino pyridine in 50 ml of dichloromethane was added dropwise a solution of 3.5 g of 2,5 dimethoxyphenylacetyl chloride in 10 ml sf dichloromethane with ice cooling and stirring. The mixture was stirred for 1 hour under ice cooling and than stirred for 2 hours at room temperature.After compeltion of the reaction, an adequate amount of an aqueous solution of sodium hydroxide was added to the reaction mixture to make the liquid alkaline and an oraganic phase was separated, washed with water, dried and concentrated under reduced pressure. The residue was purified by column chromatography using active alumina and a mixture of benzene and ethyl acetate as eluent to obtain 4.6 g of N 2 phenylethyl 2 N methyl N cyclopropylmethyl aminoethyl 2,5 dimethoxyphenylacetamide.IR absorption spectrum neat vCO 1640 cm Elementary analysis as C25H34N2O3 C H N Calcd. 73.14 8.35 6.82 Found 73.31 8.44 6.83NMR spectrum CDC13 0 1.1 m, 5H , 2.1 3.9 m, lSH , 3.73 s, 6H , 6.70 7.45 m, 8H The following compounds can be prepared in a similar manner. The results obtained are shown in Table 2 below. Table 2 EMI36.1 EMI36.2 Com. SEP No. SEP X SEP n SEP Y SEP R1 SEP R2 SEP boiling SEP liquid SEP IR absorption tb SEP point SEP condition SEP spectrum tb 1 SEP 2 OMe SEP 2 SEP SEP CH3 SEP CH2CH C CH3 2 SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 5 OMe SEP oil tb 2 SEP 4 OMe SEP 1 SEP SEP CH3 SEP CH2CH C CH3 2 SEP SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb 3 SEP 3 OMe SEP 2 SEP SEP CH3 SEP CH2CH C CH3 2 SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 4 OMe SEP oil tb 4 SEP 0 SEP SEP CH3 SEP CH2CH C CH3 2 SEP 213 216 C SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP 0.85 SEP mmHg SEP oil tb 5 SEP 4 OMe SEP 1 SEP SEP CH3 SEP CH2CH C CH3 2 SEP 220 230 C SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 1 SEP mmHg SEP oil tb 6 SEP 0 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP oil tb EMI37.1 Com. SEP No. SEP X SEP n SEP Y SEP R1 SEP R2 SEP boiling SEP liquid SEP IR absorption tb SEP point SEP condition SEP spectrum tb SEP 7 SEP 2 OMe SEP 2 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 5 OMe SEP oil tb SEP 8 SEP 3 OMe SEP 1 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb SEP 9 SEP 2 OMe SEP 2 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb 10 SEP 0 SEP SEP CH3 SEP SEP SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb 11 SEP 4 n OPr SEP 1 SEP SEP CH3 SEP SEP SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb 12 SEP 0 SEP SEP n C3H7 SEP SEP SEP yellow SEP CO 1640 SEP cm 1 tb SEP oil tb 13 SEP 4 OMe SEP 1 SEP SEP n C3H7 SEP SEP SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb 14 SEP 4 OMe SEP 1 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb EMI38.1 Com. SEP No. SEP X SEP n SEP Y SEP R1 SEP R2 SEP boiling SEP liquid SEP IR absorption tb SEP point SEP condition SEP spectrum tb 15 SEP 4 OMe SEP 1 SEP SEP CH3 SEP SEP 212 223 C SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 0.5 SEP mmHg SEP oil tb 16 SEP 0 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP oil tb 17 SEP 3 OMe SEP 2 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 4 OMe SEP oil tb 18 SEP 4 OMe SEP 1 SEP SEP CH3 SEP SEP 248 250 C SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 0.3 SEP mmHg SEP oil tb 19 SEP 0 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP OH 3250 SEP cm 1 tb SEP oil SEP CO 1620 SEP cm 1 tb 20 SEP 2 OMe SEP 2 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP OH 3250 SEP cm 1 tb SEP 5 OMe SEP oil SEP CO 1620 SEP cm 1 tb 21 SEP 2 OMe SEP 1 SEP SEP CH3 SEP SEP SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb 22 SEP 4 n OPr SEP 1 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb EMI39.1 Com. SEP No. SEP X SEP n SEP Y SEP R1 SEP R2 SEP boiling SEP liquid SEP IR absorption tb SEP point SEP condition SEP spectrum tb 23 SEP 3 OMe SEP 1 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb 24 SEP 4 OMe SEP 1 SEP SEP CH3 SEP CH2CH O CH3 2 SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP oil tb 25 SEP 2 OMe SEP 2 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 5 OMe SEP oil tb 26 SEP 3 OMe SEP 2 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP 4 OMe SEP oil tb 27 SEP 2 OMe SEP 0 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP oil tb 28 SEP 2 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1640 SEP cm 1 tb SEP oil tb 29 SEP 4 n OPr SEP 1 SEP SEP CH3 SEP SEP SEP pale SEP yellow SEP CO 1635 SEP cm 1 tb SEP oil tb The compounds were purified by column chromatography using active alumina and a mixture of benzene and ethyl acetate as eluent. EXAMPLE 9 In 30 ml of diethylether was dissolved 1 g of N 2 phenylethyl L2 N methyl N allyl aminoethyll 4 methOxy phenylacetamide, and then an adequate amount of hydrogen chloride was bubbled into the solution. The mixture was concentrated to obtain 1 g of hydrochloric acid salt of N 2 phenylethyl N 2 N methyl N allyl amino ethyl 4 methoxyphenylacetamide as a colorless gelatinlike semi solid substance having glassy appearance.